New drug combo shows promise in shrinking stomach tumors before surgery
NCT ID NCT06693128
First seen Jan 28, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This study tests whether adding the drugs camrelizumab and apatinib to standard chemotherapy before surgery can help people with advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before their planned surgery. The main goal is to see if the cancer disappears completely by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Changhai Hospital
Shanghai, China
-
Sichuan Cancer Hospital & Institute
Chengdu, China
-
Yantai Yuhuangding Hospital
Yantai, China
Conditions
Explore the condition pages connected to this study.